Back to results

Completed

10 Year Coronary Heart Disease (CHD) Risk Evaluation and Its Treatment Pattern Analysis in Postmenopausal Early Breast Cancer (EBC) Patients Taking Aromatase Inhibitors (AI)

NCT00885612

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Research Site

Cheonan, Chungcheongnam-do, South Korea

+26 additional locations

View on ClinicalTrials.gov

Save this trial

Quick facts

Start date: 2009-05
Enrollment: 1,114 participants
Sponsor: AstraZeneca

Locations (27)

Research SiteCheonan, Chungcheongnam-do, South Korea
Research SiteChuncheon, Gangwon-do, South Korea
Research SiteGoyang-si, Gyeonggi-do, South Korea
Research SiteSeongnam-si, Gyeonggi-do, South Korea
Research SitePohang, Gyeongsangbuk-do, South Korea
Research SiteMasan-si, Gyeongsangnam-do, South Korea
Research SiteAnyang, South Korea
Research SiteBusan, South Korea
Research SiteDaegu, South Korea
Research SiteDaejeon, South Korea
Research SiteGangneung, South Korea
Research SiteGuangJu, South Korea
Research SiteGwangju, South Korea
Research SiteIncheon, South Korea
Research SiteInchon, South Korea
Research SiteJeonju, South Korea
Research SiteJunam, South Korea
Research SiteKoyang, South Korea
Research SiteKyunggi, South Korea
Research SitePusan, South Korea
Research SiteSeoul, South Korea
Research SiteSeoul(Kangbuk), South Korea
Research SiteSeoul(Kangdong), South Korea
Research SiteSeoul(Kangnam), South Korea
Research SiteSeoul(Yeouido), South Korea
Research SiteSuwon, South Korea
Research SiteUlsan, South Korea

10 Year Coronary Heart Disease (CHD) Risk Evaluation and Its Treatment Pattern Analysis in Postmenopausal Early Breast Cancer (EBC) Patients Taking Aromatase Inhibitors (AI) — TrialFind